| pathology | Demonstrated benefit and harm | k | | | |
|---|
| atrial fibrillation | versus placebo or control No demonstrated result for efficacy quinidine inferior to no treatment in terms of Withdrawals due to adverse effects in Sodermark, 1975 | 6 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Hillestad, 1971 | quinidine vs no treatment | | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects ∞ [NaN; ∞] Pro-arrhythmia ∞ [NaN; ∞] Atrial fibrillation recurrence 0.74 [0.48; 1.15] | | Lloyd (quinidine vs placebo), 1984 | quinidine vs placebo | | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects ∞ [NaN; ∞] Pro-arrhythmia ∞ [NaN; ∞] Atrial fibrillation recurrence 0.84 [0.55; 1.28] | | PAFAC (quinidine vs placebo), 2004 | quinidine vs placebo | Atrial fibrillation recurrence 0.78 [0.69; 0.88] | | all cause mortality 1.05 [0.23; 4.78] Withdrawals due to adverse effects 1.10 [0.72; 1.68] Pro-arrhythmia 1.98 [0.47; 8.43] | | SOPAT (quinidine vs placebo), 2004 | quinidine vs placebo | Withdrawals due to adverse effects 0.74 [0.55; 1.00] Atrial fibrillation recurrence 0.89 [0.82; 0.96] | | all cause mortality ∞ [NaN; ∞] Pro-arrhythmia 1.29 [0.35; 4.83] | | Sodermark, 1975 | quinidine vs no treatment | Atrial fibrillation recurrence 0.73 [0.58; 0.92] | Withdrawals due to adverse effects 5.68 [1.78; 18.14] | all cause mortality 2.05 [0.42; 9.86] Pro-arrhythmia ∞ [NaN; ∞] | | Byrne Quinn, 1979 | quinidine vs placebo | Atrial fibrillation recurrence 0.79 [0.64; 0.97] | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects 1.46 [0.67; 3.16] Pro-arrhythmia ∞ [NaN; ∞] |
| Trial | Treatments | Patients | Method |
|---|
| Hillestad, 1971 | (n=-9) vs. (n=-9) | | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: | | Lloyd (quinidine vs placebo), 1984 | quinidine 1.4 g/d (n=-9) vs. placebo (n=25) | Persistent AF lasting 1 month to 3 years | double blind Parallel groups Sample size: -9/25 Primary endpoint: FU duration: 6 months | | PAFAC (quinidine vs placebo), 2004 | Quinidine 0,480 g/d (+ verapamil (n=377) vs. placebo (n=88) | Persistent AF lasting > 7 daysil | double blind Parallel groups Sample size: 377/88 Primary endpoint: FU duration: 12 months | | SOPAT (quinidine vs placebo), 2004 | Quinidine 0,320 or 0,480 g/d (+ verapamil) (n=518) vs. placebo (n=251) | Paroxysmal AF documented in the last 1 month@4 | double blind Parallel groups Sample size: 518/251 Primary endpoint: FU duration: 12 months | | Sodermark, 1975 | Quinidine 1.2 - 1.8 g/d (n=110) vs. no treatment (n=75) | Persistent AF or AFl lasting < 3 year | open Parallel groups Sample size: 110/75 Primary endpoint: FU duration: 12 months | | Byrne Quinn, 1979 | Quinidine 1.2 g/d (n=32) vs. placebo (n=42) | Persistent AF | double blind Parallel groups Sample size: 32/42 Primary endpoint: FU duration: 12 months |
|
| atrial fibrillation | versus Class Ia No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Lloyd (quinidine vs disopyramide), 1984 | quinidine vs disopyramide | | | |
| Trial | Treatments | Patients | Method |
|---|
| Lloyd (quinidine vs disopyramide), 1984 | quinidine 1.4 g/d
, quinidine 1.4 g/d
(n=28) vs. (n=29)
| Persistent AF lasting 1 month to 3 years
| double blind Parallel groups Sample size: 28/29 Primary endpoint: FU duration: 6 months
|
|
| atrial fibrillation | versus Class Ic No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Steinbeck (quinidine vs flecainide), 1988 | quinidine vs flecainide | | | |
| Trial | Treatments | Patients | Method |
|---|
| Steinbeck (quinidine vs flecainide), 1988 | Quinidine 1 g/d (+ digoxine)
, Quinidine 1 g/d (+ digoxine)
(n=15) vs. (n=15)
| Paroxysmal symptomatic AF of any duration
| open Parallel groups Sample size: 15/15 Primary endpoint: FU duration: 12 months
|
|
| atrial fibrillation | versus Class III No demonstrated result for efficacy quinidine inferior to sotalol in terms of Withdrawals due to adverse effects in Hohnloser, 1995 quinidine inferior to sotalol in terms of Withdrawals due to adverse effects in Juul-Moller, 1990 | 6 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Hohnloser, 1995 | quinidine vs sotalol | | Withdrawals due to adverse effects 10.00 [1.38; 72.39] | all cause mortality NaN [NaN; NaN] Pro-arrhythmia 3.00 [0.33; 26.92] Atrial fibrillation recurrence 0.58 [0.28; 1.23] | | Juul-Moller, 1990 | quinidine vs sotalol | | Withdrawals due to adverse effects 2.31 [1.19; 4.47] | all cause mortality 1.15 [0.07; 18.15] Pro-arrhythmia 1.15 [0.07; 18.15] Atrial fibrillation recurrence 1.13 [0.87; 1.47] | | Kalusche, 1994 | quinidine vs sotalol | | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects 2.33 [0.65; 8.40] Pro-arrhythmia 0.50 [0.05; 5.30] Atrial fibrillation recurrence 0.71 [0.43; 1.18] | | SOCESP, 1999 | quinidine vs sotalol | | | all cause mortality 0.00 [0.00; NaN] Withdrawals due to adverse effects 1.32 [0.54; 3.23] Pro-arrhythmia 0.61 [0.11; 3.54] Atrial fibrillation recurrence 1.15 [0.72; 1.84] | | PAFAC (quinidine vs sotalol), 2004 | quinidine vs sotalol | | | | | SOPAT (quinidine vs sotalol), 2004 | quinidine vs sotalol | | | |
| Trial | Treatments | Patients | Method |
|---|
| Hohnloser, 1995 | Quinidine 1 g/d (n=25) vs. sotalol 240-320 mg/dt (n=25) | Persistent AF between 2 days and 6 months | open Parallel groups Sample size: 25/25 Primary endpoint: FU duration: 6 months | | Juul-Moller, 1990 | Quinidine 1,2 g/d (n=85) vs. Sotalol 160-320 mg/dt (n=98) | Persistent AF between 2 months and 1 year | open Parallel groups Sample size: 85/98 Primary endpoint: FU duration: 6 months | | Kalusche, 1994 | Quinidine 1 g/d (n=41) vs. Sotalol 240-400 mg/dt (n=41) | AF lasting from 2 weeks to 2 years | open Parallel groups Sample size: 41/41 Primary endpoint: FU duration: 12 months | | SOCESP, 1999 | Quinidine 700 mg/d (n=63) vs. sotalol 240 mg/d (n=58) | AF lasting < 6 months | open Parallel groups Sample size: 63/58 Primary endpoint: FU duration: 6 months | | PAFAC (quinidine vs sotalol), 2004 | Quinidine 0,480 g/d (+ verapamil
, Quinidine 0,480 g/d (+ verapamil
(n=377) vs. (n=383)
| Persistent AF lasting > 7 daysil
| double blind Parallel groups Sample size: 377/383 Primary endpoint: FU duration: 12 months
| | SOPAT (quinidine vs sotalol), 2004 | Quinidine 0,320 or 0,480 g/d (+ verapamil)
, Quinidine 0,320 or 0,480 g/d (+ verapamil)
(n=518) vs. (n=264)
| Paroxysmal AF documented in the last 1 month@4
| double blind Parallel groups Sample size: 518/264 Primary endpoint: FU duration: 12 months
|
|
| atrial fibrillation | versus digoxin No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Steinbeck (quinidine vs digoxin), 1988 | quinidine vs digoxin | | | all cause mortality NaN [NaN; NaN] Withdrawals due to adverse effects ∞ [NaN; ∞] Pro-arrhythmia 2.00 [0.20; 19.78] Atrial fibrillation recurrence 0.77 [0.51; 1.16] |
| Trial | Treatments | Patients | Method |
|---|
| Steinbeck (quinidine vs digoxin), 1988 | Quinidine 1 g/d (+ digoxine) (n=15) vs. digoxine alone (n=15) | Paroxysmal symptomatic AF of any duration | open Parallel groups Sample size: 15/15 Primary endpoint: FU duration: 12 months |
|
